急性首发精神分裂症患者血浆S100B蛋白水平的变化及意义

Change of S100B plasma level of acutely psychotic patients with first-episode schizophrenia and its significance

目的探讨首发精神分裂症急性期血浆S100B蛋白水平及临床意义。方法用ELISA法检测患者血浆S100B蛋白水平,应用阳性和阴性症状量表(PANSS)评定患者精神症状。结果首发精神分裂症23例急性期血浆S100B蛋白水平(0.055±0.042)μg/L显著高于对照组(0.019±0.009)μg/L,二者差异有统计学意义(P<0.01)。首发精神分裂症治疗6周后血浆S100B蛋白水平(0.072±0.054)μg/L与治疗前(0.055±0.042)μg/L比较差异无统计学意义(P>0.05);治疗后血浆S100B持续增高者PANSS阴性症状评分较高(P<0.05)。结论S100B蛋白持续增高与首发急性精神分裂症阴性症状相关。

Objective To explore the clinical value and significance of S100B plasma level in acutely psychotic patients with first-episode schizophrenia. Methods S100B plasma levels were determined in patients by using enzyme-linked immunosorbnent assay（ELISA） . The PANSS was used to investigate psychiatric symptom. Results S100B level which was （0. 055± 0. 042） μg/L in 23 patients suffering from first-episode schizophrenia were higher than that of control group which was （0.019 ±0.009）μg/L（ P 〈 0.01 ）. There was no difference between S100B level in patients treated for 6 weeks and untrated （0.055±0. 042,0.072 ±0. 054μg/L respectively,P 〉 0.05 ）. PANSS negative scores of patients were more and more higher with the S100B level in plasma continuing to increase after treatment （ P 〈 0. 05）. Conclusions Continuously increased S100B level are associated with negative symptomatology in acute schizophrenia; schizophreniform psychosis patients.